These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 21372028)
1. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Jacobs I; Menon U Cancer Prev Res (Phila); 2011 Mar; 4(3):299-302. PubMed ID: 21372028 [TBL] [Abstract][Full Text] [Related]
2. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Mai PL; Wentzensen N; Greene MH Cancer Prev Res (Phila); 2011 Mar; 4(3):303-6. PubMed ID: 21372029 [TBL] [Abstract][Full Text] [Related]
3. Personalizing CA125 levels for ovarian cancer screening. Dorigo O; Berek JS Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498 [TBL] [Abstract][Full Text] [Related]
4. Ovarian Cancer Biomarkers: Moving Forward in Early Detection. Bonifácio VDB Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708 [TBL] [Abstract][Full Text] [Related]
5. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. Campan M; Moffitt M; Houshdaran S; Shen H; Widschwendter M; Daxenbichler G; Long T; Marth C; Laird-Offringa IA; Press MF; Dubeau L; Siegmund KD; Wu AH; Groshen S; Chandavarkar U; Roman LD; Berchuck A; Pearce CL; Laird PW PLoS One; 2011; 6(12):e28141. PubMed ID: 22163280 [TBL] [Abstract][Full Text] [Related]
6. E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. Kothandaraman N; Bajic VB; Brendan PN; Huak CY; Keow PB; Razvi K; Salto-Tellez M; Choolani M BMC Cancer; 2010 Feb; 10():64. PubMed ID: 20181230 [TBL] [Abstract][Full Text] [Related]
7. Protein biomarkers of ovarian cancer: the forest and the trees. Nolen BM; Lokshin AE Future Oncol; 2012 Jan; 8(1):55-71. PubMed ID: 22149035 [TBL] [Abstract][Full Text] [Related]
8. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Zhang M; Cheng S; Jin Y; Zhao Y; Wang Y Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188503. PubMed ID: 33421585 [TBL] [Abstract][Full Text] [Related]
9. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Rustin GJ; Bast RC; Kelloff GJ; Barrett JC; Carter SK; Nisen PD; Sigman CC; Parkinson DR; Ruddon RW Clin Cancer Res; 2004 Jun; 10(11):3919-26. PubMed ID: 15173101 [No Abstract] [Full Text] [Related]
10. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Lawicki S; Gacuta-Szumarska E; Będkowska GE; Szmitkowski M Growth Factors; 2012 Dec; 30(6):357-66. PubMed ID: 22988839 [TBL] [Abstract][Full Text] [Related]
11. CA-125 might be good predictive tumor biomarker for earlier detection of serosal metastases including the ovarian metastasis in high-risk invasive lobular breast cancer. Abduyev Z; Altundag K J BUON; 2019; 24(4):1735. PubMed ID: 31646834 [No Abstract] [Full Text] [Related]
17. Androgens and epithelial ovarian cancer: What's the connection? Li AJ; Karlan BY Cancer Biol Ther; 2008 Nov; 7(11):1712-6. PubMed ID: 19151584 [No Abstract] [Full Text] [Related]
18. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. Moore RG; Bast RC J Clin Oncol; 2007 Sep; 25(27):4159-61. PubMed ID: 17698803 [No Abstract] [Full Text] [Related]